[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infection":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,53,79,115,139,162,188,216,255,279,315,348,374,406,437,464,495,518,546,579,598,625,647,672,708],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100635701","phase-4-the-vancomycin-piperacillintazobactam-vpt-patient-safety-trial-vps-100635701",false,"NCT07556107","The Vancomycin Piperacillin\u002FTazobactam (VPT) Patient Safety Trial (VPS)","A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin\u002FTazobactam or Meropenem: VPT Patient Safety (VPS) Study","VPS","Inclusion criteria\n\n1. Hospitalized or being hospitalized.\n2. Age \\>\u002F=18 yr old.\n3. Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician.\n4. Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively).\n5. Consenting\u002Fenrollment will not clinically significantly delay abx administration.\n6. Baseline and \\>\u002F=1 prior Scr available (within 1 yr).\n7. Pt or LAR able to provide IC. Exclusion criteria\n\n1\\. AKI (\\>\u002F=moderate) (KDIGO stage 2-3) (Scr increase \\>\u002F=2-fold from chronic BL) (Scr based).\n\n2\\. CKD (\\>\u002F=moderately to severely decreased eGFR) (KDIGO stage G3b-G5) (by history or eGFR \\\u003C\u002F=44 mL\u002Fmin\u002F1.73M2) (Scr based).\n\n3\\. Beta lactam allergy. 4. Contraindication to VPT or VM. 5. Infection requiring VPT or VM specifically or another abx regimen. 6. Participation in another research study with interventions that may impact study endpoints.","ALL","18 Years",{"count":21,"type":22},852,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.",[28,29,30],"Infection","Acute Kidney Injury","Sepsis",[32,33,34,35,36,37,38,39],"infection","hospitalized","AKI","cystatin c","vancomycin","piperacillin\u002Ftazobactam","meropenem","RCT","RECRUITING","2026-08-16",{"date":43,"type":44},"2026-08-18","ACTUAL",{"date":46,"type":22},"2026-08-17",{"date":48,"type":22},"2028-12-31",{"name":50,"class":51},"Bassett Healthcare","OTHER",3,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100652116","procalcitonin-as-a-prognostic-predictor-in-patients-with-acute-infectious-disease-hospitalized-in-the-internal-medicine-department-100652116","NCT07770334","Procalcitonin as a Prognostic Predictor in Patients With Acute Infectious Disease Hospitalized in the Internal Medicine Department.","Inclusion Criteria:\n\n* All patients hospitalized in internal medicine and geriatric wards with a diagnosis of acute infectious disease who underwent procalcitonin testing, starting in 2020.\n\nExclusion Criteria:\n\n* Age under 18\n* Causes for false positive elevated cacitonin:\n* Extensive burns\n* Major operation in the last 30 days\n* Major trauma in the last 30 days.\n* Severe pancreatitis\n* Cardiogenic shock\n* Small Cell Lung Cancer\n* Thyroid gland malignancy",{"count":60,"type":22},1000,"OBSERVATIONAL","Procalcitonin is a well-known biomarker used to distinguish between bacterial and viral infections, assess a patient's risk category, and serve as a prognostic indicator. However, existing data are derived primarily from relatively young patients in intensive care units; there is a lack of information regarding the prognostic significance of procalcitonin in older patients hospitalized in internal medicine wards.",[64,28,65],"Procalcitonin","Internal Medicine Patients",[64,67,68,69],"CRP","Acute Infection","Internal Medicine Ward","NOT_YET_RECRUITING","2026-08-13",{"date":43,"type":44},{"date":74,"type":22},"2026-09-01",{"date":76,"type":22},"2026-12-31",{"name":78,"class":51},"Barzilai Medical Center",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100651005","clinical-assessment-and-treatment-in-the-nursing-home-as-an-alternative-to-hospital-admission-100651005","NCT07756554","Clinical Assessment and Treatment in the Nursing Home as an Alternative to Hospital Admission","Home-Based Assessment and Treatment by Municipal Acute Care Teams Combined With Remote Senior Physician Consultation as an Alternative to Hospital Admission for Nursing Home Residents: A Multicenter Randomized Controlled Trial","Clusters (Nursing Homes):\n\nInclusion Criteria:\n\n* Nursing homes, defined as long-term care facilities with care personnal available 24\u002F7 for residents with need for continued medical care\n* Nursing homes located in the Capital Region of Denmark\n* Nursing homes accepting participation and cluster randomization\n\nExclusion criteria\n\n* Assisted living facilities, intermediate\u002Ftemporary care units, rehabilitation units, hospices, or other non-nursing-home setting.\n* Nursing homes located on the island of Bornholm",{"count":87,"type":22},9000,[89],"NA","This multicenter, cluster-randomized, unblinded quality-improvement study evaluates whether home-based clinical assessment by municipal acute care teams can safely reduce hospital admissions among nursing home residents experiencing acute illness or clinical deterioration during out-of-hours periods. Participating nursing homes in the Capital Region of Denmark will be randomized to either usual care (contacting the regional medical helpline, 1813) or the intervention pathway, in which nursing home staff contact a municipal acute care team directly. The acute care team performs an on-site clinical assessment and, when needed, consults a senior physician in the hospital emergency department to establish a treatment and observation plan, which may include continued management at the nursing home under hospital responsibility. The study compares the intervention with usual care with respect to hospital admissions and mortality among nursing home residents.",[92,93,28,94,95],"Nursing Homes Residents","Deterioration, Clinical","Dehydration","Pain Management",[97,98,99,100,101,102,103,104],"hospital at home","admission avoidance","home-based treatment","nursing home residents","Hospital-at-Home","HaH","HITH","Hospital in the home","2026-08-06",{"date":107,"type":44},"2026-08-10",{"date":109,"type":44},"2026-02-01",{"date":111,"type":22},"2027-12",{"name":113,"class":51},"Copenhagen University Hospital at Herlev",4,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":18,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":4,"leadSponsor":135,"locationsCount":138},"100099544","diagnosis-and-management-of-inflammatory-and-infectious-diseases-100099544","NCT00557726","Diagnosis and Management of Inflammatory and Infectious Diseases","* INCLUSION CRITERIA:\n\n  1. Known or suspected exposure to infection, as determined by the Principal Investigator OR Presence of signs and symptoms of an infectious or inflammatory disease\n  2. Age range: 3 years of age and older.\n  3. NIAID\u002FLIR investigator who has an interest in the patient s illness and is willing to serve as attending physician to supervise the patient's medical care at the NIH.\n  4. Primary physician outside the NIH\n  5. The patient or the patient's Legally Authorized Representative is capable of informed consent and signs the consent form. The consent form will be signed by parents or guardians of patients under the age of 18\n\nEXCLUSION CRITERIA:\n\n1. Pregnant.\n2. Presence of conditions that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.","3 Years","100 Years",{"count":124,"type":22},400,"This protocol is being established to cover the evaluation of patients with inflammatory and\u002For infectious diseases which are not covered under previously existing protocols. The purpose of such a protocol is that frequently patients are referred to us with either diagnosed or undiagnosed illnesses which would be of interest to our teaching program or which would serve as a source of patients to subsequently be entered into established, ongoing protocol studies. Such patients will be admitted to the protocol and handled according to accepted medical practice of diagnosis and treatment.",[28,127],"Inflammation",[127,28,129,130],"Fever","Natural History",{"date":132,"type":44},"2026-08-07",{"date":134,"type":44},"1978-02-17",{"name":136,"class":137},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":18,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":138},"100648328","surgical-recovery-support-pillow-for-spine-surgeries-100648328","NCT07720856","Surgical Recovery Support Pillow for Spine Surgeries","Inclusion Criteria:\n\n* Adult patients who have lumbar fusion surgery, who consent to participate\n\nExclusion Criteria:\n\n* Pediatric patients 18 years old and under",true,"19 Years",{"count":148,"type":22},10,[89],"The present study investigates the feasibility of a support pillow for use after spinal surgical procedures, and more particularly, to protect the midline region of the back following spinal surgery.\n\nExisting cushioning pillows do not accommodate the anatomy of the human back nor the requirements of isolating a vertical spinal incision. For example, donut-style or ring-shaped pillows are designed for entirely different purposes, such as hemorrhoidal relief, and cannot provide the desired spinal relief. As a result, there is no suitable, dedicated support structure that allows a patient to rest on their back while eliminating pressure on the surgical site. Accordingly, there is a need for a device that permits postoperative spinal surgery patients to sit or lie in a supine or reclined position without the surgical incision contacting or being compressed by any supporting surface.",[152,28],"Spine Surgery Complications",[154],"Post-surgical pillow","2026-08-05",{"date":132,"type":44},{"date":107,"type":22},{"date":159,"type":22},"2026-09-30",{"name":161,"class":51},"Montefiore Medical Center",{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":170,"targetDuration":172,"studyType":61,"phases":4,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":187},"100623519","early-sepsis-recognition-tool-100623519","NCT07397689","Early Sepsis Recognition Tool","Sepsis Optimal Recognition Toolkit in Children (SORT): An Early Recognition Tool for Children in Asia","SORT","Inclusion Criteria:\n\n* Children \\\u003C 18 years old\n* Suspected infection defined by (1) blood culture performed (irrespective of result), AND (2) use of broad-spectrum anti-microbial agents, in the first 24 hours of admission\n\nExclusion Criteria:\n\n* 18 years and older\n* Patients who discharge At Own Risk (AOR) without outcome data",{"count":171,"type":22},40000,"30 Days","This study seeks to develop early recognition tools specially designed for children meeting the Phoenix definition and explore implementation science aspects by investigating facilitators and barriers to adopting Phoenix sepsis criteria in clinical practice. This addresses the critical need for systemic, evidence-based approaches to paediatric sepsis identification across diverse healthcare settings in Asia.",[28,30],[176,177,32,178],"Phoenix sepsis score","early recognition","child","2026-08-04",{"date":132,"type":44},{"date":109,"type":44},{"date":183,"type":22},"2028-12",{"name":185,"class":186},"KK Women's and Children's Hospital","OTHER_GOV",19,{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":195,"minAge":19,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":138},"100453852","phase-1-nadph-oxidase-correction-in-mrna-transfected-granulocyte-enriched-cells-in-chronic-granulomatous-disease-cgd-100453852","NCT05189925","NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)","NADPH Oxidase Correction in mRNA Transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)","* INCLUSION CRITERIA:\n\nIndividuals must meet all of the following criteria to be eligible for study participation:\n\n* Males aged 18 to 75 years\n* CGD confirmed by DHR and deficiency subtype confirmed by protein analysis and\u002For genetic sequencing\n* Has a physician at home for follow-up care\n* Able to provide informed consent\n* For men who engage in activities that can result in pregnancy, agree to use contraception when engaging in sexual activities that can result in pregnancy. Contraception must be used from screening through 3 months after the CGD-Grans infusion. Acceptable methods of contraception include the following:\n\n  * Hormonal contraception\n  * Male or female condom\n\nEXCLUSION CRITERIA:\n\nIndividuals meeting any of the following criteria will be excluded from study participation:\n\n* Clinically unstable due to moderate to severe acute systemic infections as defined by persistent resting tachypnea, tachycardia, or hypoxia of \\>20% from baseline and hypotension.\n* Current or history of stage 4 chronic kidney disease or estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2 within 90 days of baseline.\n* Unstable diabetes mellitus with hemoglobin A1c \\>7.0% and fasting serum glucose \\>200 mg\u002FdL at screening.\n* Current or history of heart failure stage D as defined by the American College of Cardiology Foundation\u002FAmerican Heart Association guidelines.\n* History of arrhythmias that are symptomatic and deemed clinically unsafe for participation by NIH CC Cardiology consultation.\n* Current or history of invasive cancers that require chemotherapy within 5 years of screening.\n* Active hepatitis B, C, or HIV infections at screening.\n* Unstable hypertension requiring addition of new anti-hypertensives within 2 weeks of screening.\n* Impaired renal function that is unstable, with serum creatinine \\>3.0 mg\u002FdL and rising.\n* Serum transaminases and bilirubin that are \\>3 x the upper limit of normal.\n\nNOTE: For prospective subjects who, per PI assessment at screening, have abnormal liver function tests, and\u002For a significant history of liver disease, and\u002For liver-related complications of CGD, and who otherwise meet eligibility criteria \\[i.e. those who do NOT meet any of the exclusion set forth herein\\], a hepatology consult will be required at screening, and participation must be approved in writing by hepatology to the PI.\n\n* Electrocardiogram abnormalities indicative of acute myocardial injury, or arrhythmias that presents anesthetic risks, at screening.\n* Anemia with hemoglobin \\\u003C8 g\u002FdL (transfusions to correct anemia permitted).\n* Thrombocytopenia (platelets \\\u003C50 x10\\^9 cells\u002FL) (platelet transfusions to correct thrombocytopenia permitted).\n* Profound thrombocytopenia (platelet counts \\\u003C10,000\u002Fmicroliter) that is not reversible with platelet transfusions.\n* Abnormal prothrombin time\u002Fpartial thromboplastin time (PT\u002FPTT) values outside the ranges accepted at the NIH CC that are not corrected or that cannot be attributed to presence of Lupus anticoagulant (commonly found in CGD patients).\n* Inherited bleeding disorder that precludes line placement.\n* Severe oxygen-dependent pulmonary disease that increases risks of procedures that may require sedation.\n* History of or current evidence of alcohol or illicit drug abuse or dependence.\n* Participation in a clinical protocol that includes an intervention that, in the opinion of the investigator, may affect the results of the current study.\n\nSubjects will be selected in an equitable manner from the available pool of potentially eligible individuals, without regard to factors such as gender, race, ethnicity, socioeconomic status, etc, except for age and sex.","MALE","75 Years",{"count":7,"type":22},[199],"PHASE1","Background:\n\nCGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells.\n\nObjective:\n\nTo test a procedure in which mRNA is added to a person s blood cells.\n\nEligibility:\n\nMales aged 18-75 with CGD with a mutation in the gene that makes the protein gp91phox.\n\nDesign:\n\nParticipants will be screened with:\n\nMedical history\n\nPhysical exam\n\nBlood and urine tests\n\nSwab to test for strep throat\n\nSome screening tests will be repeated during the study.\n\nParticipants will be admitted to the NIH Clinical Center hospital for at least 7 days. They will have apheresis. For this, a medicine is injected under their skin to prepare their white blood cells for collection. An IV line is placed into an arm vein. Blood goes through the IV line into a machine that divides whole blood into red blood cells, plasma, and white blood cells. The white blood cells are removed, and the rest of the blood is returned to the participant through an IV line in their other arm. The next day, they will get their mRNA-corrected cells via IV. They will be monitored for 3 more days.\n\nAfter discharge, participants will keep a symptom diary. They will be contacted weekly for one month, and then once a month. They will have a follow-up visit 3 months after the infusion.",[202,28],"Chronic Granulomatous Disease",[204,205,206,207],"Primary Immune Deficiency","systemic infection","autologous transfusion","Apheresis","2026-07-25",{"date":210,"type":44},"2026-07-28",{"date":212,"type":44},"2022-07-22",{"date":214,"type":22},"2027-07-01",{"name":136,"class":137},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":228,"conditions":229,"keywords":238,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":52},"100624287","phase-3-prediction-and-prevention-of-bloodstream-infections-after-kidney-transplantation-100624287","NCT07407673","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study","PREDICT","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Kidney transplant recipient.\n3. Able to provide written informed consent.\n4. ≥1 urine sample with bacteriuria ≥10\\^5 CFU\u002FmL (excluding fungi) within first month post-transplantation.\n\nExclusion Criteria:\n\n1. Known strictures in the esophagus and\u002For obstructions in the gastrointestinal tract including diabetes gastroparesis.\n2. Known hypersensitivity or allergy to β-lactam antibiotics.\n3. Known or suspected genetic metabolism anomalies in the carnitine metabolism, including carnitine transporter defect or organic acidurias such as methylmalonic aciduria or propionic acidaemia.\n4. Individuals of Faroese descent (defined as both biological parents born in the Faroe Islands).\n5. Porphyria.\n6. Current treatment with valproic acid, valproate or other medications liberating pivalic acid.\n7. Current treatment with probenecid.\n8. Current treatment with methotrexate.\n9. Ongoing dialysis one month post-transplantation.\n10. Pregnancy or breastfeeding.",{"count":225,"type":22},180,[227],"PHASE3","Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs). Some of these infections can spread to the bloodstream and cause serious illness, hospitalization, loss of kidney function, or death. Currently, there is no established strategy to prevent these serious bacterial infections in kidney transplant recipients who are at highest risk.\n\nThe PREDICT study is investigating whether a low daily dose of the antibiotic pivmecillinam can reduce the risk of bacterial urinary tract infections and bloodstream infections after kidney transplantation. The study focuses on kidney transplant recipients who have bacteria detected in their urine during the first month after transplantation, as previous research suggests that these patients have a particularly high risk of developing serious infections later.\n\nIn this randomized, double-blind, placebo-controlled trial, 180 adult kidney transplant recipients will be assigned by chance to receive either pivmecillinam or a matching placebo from 1 to 6 months after transplantation. Neither participants nor study staff will know which treatment has been assigned during the study. All participants will continue to receive standard post-transplant care and monitoring.\n\nThe main goal of the study is to determine whether prophylactic pivmecillinam can reduce the occurrence of infections caused by Enterobacterales bacteria, including urinary tract infections and bloodstream infections, during the first 6 months after transplantation. The study will also evaluate the effects of treatment on serious clinical outcomes, safety, quality of life, antimicrobial resistance, and long-term kidney transplant outcomes.\n\nThe study hypothesis is that targeted antibiotic prophylaxis with pivmecillinam in kidney transplant recipients at increased risk of infection will reduce the incidence of Enterobacterales urinary tract infections and bloodstream infections during the high-risk period after transplantation compared with placebo.",[230,231,232,233,28,234,235,236,237],"Kidney Transplant Infection","Bloodstream Infection","Kidney Transplant","Kidney Transplant Recipients","Urinary Tract Infection(UTI)","Urinary Tract Infection Bacterial","Antibiotic Prophylaxis","Bacteriuria",[239,240,241,242,243,244,245],"kidney transplantation","bloodstream infection","urinary tract infection","antibiotic prophylaxis","pivmecillinam","bacteriuria","Enterobacterales","2026-07-20",{"date":248,"type":44},"2026-07-22",{"date":250,"type":22},"2027-01-01",{"date":252,"type":22},"2041-07",{"name":254,"class":51},"Susanne Dam Nielsen, MD, DMSc",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":264,"conditions":265,"keywords":268,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":138},"100590956","metagenomics-for-ocular-inflammation-100590956","NCT06974162","Metagenomics for Ocular Inflammation","Metagenomic Sequencing of Ocular Fluids in Patients With Ocular Inflammation","Inclusion Criteria:\n\n1. 18 years of age or older with the capacity to consent\n2. Standard of care has not determined a clinical diagnosis\n3. Active ocular inflammation with risk of visual loss\n4. Clinically suspected infectious or para-infectious cause of ocular inflammation\n\nExclusion Criteria:\n\n1. Contraindication to ocular fluid sampling\n2. Where an urgent result within 5 days is clinically required",{"count":263,"type":22},36,"The aim of this study is to apply a diagnostic test called 'metagenomic sequencing' to identify the involvement of potential infections in patients with ocular inflammation, where this hasn't been detected by currently available standard testing. For many people with ocular inflammation, no cause is ever found for their disease. In some cases, an infection or infectious trigger is suspected, but currently available tests are inadequate. Metagenomic sequencing can identify almost every globally known infection (bacteria, virus, fungi, parasites) in a sample. Therefore, it has the potential to identify an infection that has caused or triggered ocular inflammation, and as a consequence may help to identify specific treatments. It has the potential to improve our understanding of how to diagnose and treat people with this problem. This study will allow us to test the technique that has been previously optimised for brain infections, on ocular fluids. Participants will be 18 years of age or over and have active ocular inflammation which is suspected to be due to an infection, or an autoimmune process which has been triggered by an infection, but identification of this infection has not been possible using the investigations available as part of standard NHS care. Participants will be identified by the treating clinical team as requiring a sample of fluid from inside of the eye, and some of this fluid will be sent for metagenomic sequencing alongside standard testing. This study will be conducted at Moorfields Eye Hospital, London and will last for approximately a year. Participants will undergo additional non-invasive ocular imaging on the day of their clinic visit, but will not have to attend any additional research visits.",[266,267,28],"Uveitis","Aqueous Humor",[269,266,267,270],"Metagenomics","Ophthalmology",{"date":272,"type":44},"2026-07-21",{"date":274,"type":44},"2025-06-12",{"date":276,"type":22},"2027-11-27",{"name":278,"class":51},"Moorfields Eye Hospital NHS Foundation Trust",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":290,"conditions":291,"keywords":298,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":313,"locationsCount":138},"100647332","drone-wound-study-severe-infection-after-drone-related-combat-trauma-100647332","NCT07706608","DRONE-WOUND Study: Severe Infection After Drone-Related Combat Trauma","DRONE-WOUND Study: Tissue Devitalization and Severe Infection Following Drone-Related Combat Trauma: A Prospective Multicenter Observational Cohort Study","DRONE-WOUND","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Combat-related injury caused by a confirmed drone-related mechanism, including first-person view (FPV) drones, drone-delivered explosive munitions, or other unmanned aerial vehicle (UAV)-associated injuries.\n* Open extremity injury requiring operative surgical debridement.\n* Hospital admission within 24 hours after injury.\n* Written informed consent provided by the participant or legally authorized representative, in accordance with local regulations.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Isolated superficial soft tissue injuries not requiring operative treatment. Injuries requiring immediate primary amputation before initial surgical assessment.\n* Patients transferred more than 24 hours after injury.\n* Pre-existing active infection involving the injured limb before the combat injury.\n* Patients who die before completion of the initial surgical debridement.\n* Prisoners or other individuals unable to provide informed consent when no legally authorized representative is available.","60 Years",{"count":289,"type":22},500,"Drone-related combat injuries have become one of the most devastating mechanisms of injury in modern warfare. These injuries often cause extensive tissue devitalization, contamination, open fractures, vascular injuries, and complex soft tissue damage, which may substantially increase the risk of severe wound infection, multidrug-resistant bacterial infection, repeated surgical procedures, limb loss, and sepsis. However, the relationship between the extent of tissue devitalization and the development of severe infection has not been systematically investigated.\n\nThe DRONE-WOUND Study is a prospective observational cohort study designed to evaluate the association between tissue devitalization and severe wound infection in patients with drone-related combat trauma. The study will collect detailed clinical, surgical, microbiological, and radiological data from injured patients treated at participating trauma centers. Measures of tissue injury, contamination, surgical management, microbiological findings, and infection outcomes will be analyzed to identify factors associated with severe infection and poor clinical outcomes.\n\nThe findings of this study are expected to improve understanding of the mechanisms leading to infection after drone-related injuries, support early identification of high-risk patients, and inform future strategies for surgical management, antimicrobial therapy, and infection prevention in combat trauma. Ultimately, the study aims to improve limb salvage, reduce infectious complications, and enhance outcomes for patients with severe drone-related injuries.",[292,293,28,294,295,296,297],"Combat Related Symptoms","Combat Trauma","Infection Complication","Wound - in Medical Care","Wound Infection Post-Traumatic","Surgical Site Infection (SSI)",[299,293,300,301,302,303,304,305,306],"Drone-Related Injury","Tissue Devitalization","Wound Infection","Severe Wound Infection","Surgical Site Infection","Multidrug-Resistant Organisms","Antimicrobial Resistance","Soft Tissue Injury","2026-07-11",{"date":309,"type":44},"2026-07-16",{"date":311,"type":22},"2026-10-23",{"date":311,"type":22},{"name":314,"class":51},"Ukrainian Society of Regional Anesthesia and Pain Therapy",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":324,"conditions":325,"keywords":329,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":347},"100425529","persona-revision-knee-system-outcomes-100425529","NCT04821154","Persona Revision Knee System Outcomes","Clinical Investigation to Demonstrate Performance, Safety and Clinical Benefits of the Persona Revision Knee System","Inclusion Criteria:\n\n1. Male or female of at least 18 years of age at the time of screening.\n2. Signed an institutional review board approved informed consent.\n3. Willingness and ability to comply with the study procedures and visit schedules and ability to understand and follow oral and written post-operative care instructions.\n4. Previous medical diagnosis\u002F history of at least one of the following conditions requiring treatment using the Persona Revision Knee System within a pre-specified study variant configuration (cohort), in accordance with the instructions for use (IFU):\n\n   1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis or polyarthritis\n   2. Collagen disorders, and\u002For avascular necrosis of the femoral condyle\n   3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy\n   4. Moderate valgus, varus, or flexion deformities\n   5. The salvage of previously failed surgical attempts or for a knee in which satisfactory stability in flexion cannot be obtained at the time of surgery\n5. A pre-operative Knee Society Knee Score (objective assessment) ≤ 80.\n\nExclusion Criteria:\n\n1\\) Presence of clinically observed active or suspected latent infection in the affected joint at the time of procedure.\n\n3\\) Presence of of local\u002Fsystemic\u002Fdistant focal infection that may affect or hematogenously spread to the prosthetic joint.\n\n4\\) Skeletal immaturity or insufficient bone stock on femoral or tibial surfaces which cannot provide adequate support and\u002For fixation to the prosthesis.\n\n5\\) Diagnosed with neuropathic arthropathy, osteoporosis, or any loss of musculature or neuromuscular disease that compromises the affected limb.\n\n6\\) Presence of a stable, painless arthrodesis in a satisfactory functional position in the affected joint.\n\n7\\) Severe instability of the affected joint secondary to the absence of collateral ligament integrity.\n\n8\\) Diagnosis of rheumatoid arthritis in conjunction with any of the following at the time of screening:\n\n1. An ulcer of the skin\n2. History of recurrent breakdown of the skin\n3. Use of steroids\n\n   9\\) Patient requires simultaneous bilateral knee surgery for treatment of diagnosed condition.\n\n   10\\) Pregnant or women planning to become pregnant during the time they will be participating in the study.\n\n   11\\) Any documented clinically significant degree of cognitive impairment or other condition, finding, or psychiatric illness at screening which, in the opinion of the Investigator, could compromise patient safety or interfere with the assessment of the safety and treatment effects of the study procedure.\n\n   12\\) Any patient who is institutionalized, or with a known drug or alcohol dependence currently or within the last year.",{"count":323,"type":22},380,"The study will evaluate the performance, clinical benefits and safety of the Persona Revision Knee System in patients who have received primary or revision total knee arthroplasty (TKA) treatment. This will be done using a multicenter, single-arm, consecutive series, retrospective cohort study with prospective follow-up.",[326,28,327,328],"Arthroplasty Complications","Knee Disease","Knee Osteoarthritis",[330,331,332,333,334,335,336],"Revision","Total Knee","Medical Device","Safety","Performance","Primary","Clinical Benefits","2026-07-09",{"date":339,"type":44},"2026-07-10",{"date":341,"type":44},"2021-06-14",{"date":343,"type":22},"2033-12-31",{"name":345,"class":346},"Zimmer Biomet","INDUSTRY",16,{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":356,"maxAge":19,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":373},"100429750","phase-4-single-dose-intravenous-antibiotics-for-complicated-urinary-tract-infections-in-children-100429750","NCT04876131","Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children","CHOICE UTI - Clinical Efficacy of Single Dose (Daily) IV Antibiotics Followed by 2 Days Oral Antibiotics Compared to 3 Doses (Daily) IV Antibiotics for Children With Complicated Urinary Tract Infections: a Multicentre Randomised Trial","CHOICE UTI","Inclusion Criteria:\n\n* 3 months (corrected age) to 18 years\n* Fever (reported fever at home or measured fever of ≥38 degrees Celsius associated with the illness that triggered current ED presentation (eg fever may have been 18 hours prior to presentation but none since then because patient has been on maximal antipyretics - paracetamol or ibuprofen)\n* Any of the following complicating features: Vomiting, Rigors, History of recurrent UTI, Urological abnormalities, Tachycardia\n* Urine sample available (Urine culture must have been collected prior to or within an hour of antibiotic treatment, either at the GP or ED - in order to assess urine culture as per below).\n* Abnormal urinary dipstick leucocyte esterase \\>1+ or nitrite positive OR ≥5 White Blood Cells (WBCs) per high-power field in centrifuged urine OR≥ 10 White Blood Cells (WBCs) per mm3 in uncentrifuged urine and bacteriuria with any bacteria per high-power field\n* ED clinician determines the child requires treatment with IV antibiotics \\* In ED, only urine dipstick or urinalysis will be available. Once urine culture is available, to be included in the efficacy analysis, culture results must meet the following criteria: Positive urine culture result with no more than 2 species of microorganisms AND Spontaneously voided urine with ≥105 microorganisms per mL of urine or Suprapubic aspirate or urinary catheter with ≥104 microorganisms per mL of urine. In the absence of a positive urine culture, ultrasonographic findings supporting pyelonephritis (per reporting radiologist) will be accepted as evidence of a urinary tract infection.\n\nExclusion Criteria:\n\n* Sepsis (requiring inotropic support or more than 20ml\u002Fkg of fluid bolus in Emergency Department)\n* Known allergy to all once daily study drug options (gentamicin or ceftriaxone or amikacin)\n* If the patient has another co-existing condition which requires (based on established evidence-based guidelines) more than 1 dose of IV antibiotics eg meningitis\n* Known chronic renal failure or renal transplant patients\n* Unrepaired posterior urethral valves\n* Indwelling stent and fever\n* Previously enrolled participants in the CHOICE UTI trial.\n* No available oral antibiotic option for this UTI: urine culture result already available and multi-resistant organism with susceptibility only to IV antibiotics or known intolerance to oral antibiotics (previous UTI with multi-resistant organism not an exclusion)\n* Previous IV antibiotics for same UTI episode eg interhospital transfer whereby significant time has passed since first dose IV\n* Patients with clinically suspected renal abscess e.g., extreme renal tenderness, out of keeping with pyelonephritis (clinically determined).\n* Clinician does not intend on prescribing a course of IV antibiotics but plans on only giving a single dose from the outset\n* Recurrence of urinary tract infection within 2 weeks\n* Unable to obtain consent\n* Patient is pregnant","3 Months",{"count":358,"type":22},452,[25],"Urinary tract infections (UTI) are commonly encountered in children, with 7% diagnosed with at least one UTI by the age of 19 years. The evidence for treatment of uncomplicated UTI is clear; oral antibiotics are as good as intravenous (IV) antibiotics, usually for a total of 7 days. Complicated UTIs (cUTIs) on the other hand, are common reasons for hospital admissions for IV antibiotics and constitute a major burden for healthcare systems. There is considerable variation in care for children who present with UTI and have complicating features such as vomiting, dehydration, urological abnormalities or have a previous history of UTI. Australian and international guidelines lack clear, evidence-based recommendations to guide treatment in this group. Without gold standard evidence, these children will continue to receive unnecessary IV antibiotics, longer hospital stays and poorer health outcomes.\n\nThis multicentre, non-inferiority randomised trial will investigate if One dose - single dose of IV followed by 2 days oral antibiotics is as non-inferior to Three doses for children with UTI and co-existing complicating factors presenting to the Emergency Department (ED). In other words, this study will compare if a single dose of IV antibiotics plus two days oral antibiotics is as clinically effective as 3 doses antibiotics in resolving UTI symptoms at 72 hours after the first dose of IV antibiotics, for complicated UTIs in children presenting to the ED. All participants will receive a total of 7 days of antibiotics for the complicated urinary tract infection. If 1 dose IV and 2 days oral antibiotics is found to be as good as 3 days, the duration of IV antibiotics for complicated UTI can be reduced along with avoidance of the inherent risks of unnecessary hospital admission by administering a single IV dose in an outpatient\u002FED setting. On the other hand if a single IV dose results in prolonged symptoms or treatment failure, this will inform practice for the proportion of children who have a single dose of IV antibiotics in the ED and are sent home on oral antibiotics. Regardless of the outcome, this trial will inform clinical practice for complicated UTI to improve health outcomes for this group.",[362,28,363],"Complicated Urinary Tract Infection","Pediatric Infectious Disease","2026-07-06",{"date":366,"type":44},"2026-07-08",{"date":368,"type":44},"2022-05-30",{"date":370,"type":22},"2028-05-16",{"name":372,"class":51},"Murdoch Childrens Research Institute",7,{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":390,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":402,"leadSponsor":404,"locationsCount":138},"100644116","phase-3-naproxen-versus-placebo-as-adjunct-treatment-of-cellulitis-100644116","NCT07665476","Naproxen Versus Placebo as Adjunct Treatment of Cellulitis","Naproxen Versus Placebo as Adjunct Treatment of Cellulitis: A Randomized Controlled Trial","NVP","Inclusion Criteria:\n\n* adults (age ≥18 years)\n* diagnosed with cellulitis and\n* determined by the treating physician to be eligible for outpatient treatment with oral cephalexin\n\nExclusion Criteria:\n\nThese are appropriate exclusions according to eligibility for treatment with naproxen in clinical practice, and the investigators believe that relatively few patients will be excluded.\n\nThe investigators will exclude participants for any of the following reasons:\n\n1. Age \\\u003C18 years;\n2. Patient already taking oral antibiotics or NSAIDs;\n3. Treating physician decides IV antibiotics are required;\n4. Skin abscess requiring incision and drainage;\n5. Known prior skin or soft tissue infection secondary to methicillin-resistant Staphylococcus aureus (MRSA);\n6. Cellulitis secondary to a human or animal bite;\n7. Penetrating wound or water exposure resulting in cellulitis;\n8. Surgical site infection;\n9. Pregnancy or breastfeeding;\n10. Prior gastric bypass surgery;\n11. Patients on dual antiplatelet therapy;\n12. Patients on warfarin, low molecular weight heparin, or direct oral anticoagulant therapy;\n13. Severe uncontrolled heart failure, or coronary artery bypass grafting (CABG) surgery within 14 days prior to the index visit, or planned CABG surgery within 21 days following the index visit.;\n14. History of gastric\u002Fduodenal ulcer or gastrointestinal bleeding in the past 12 months;\n15. Known kidney impairment with an estimated glomerular filtration rate \\\u003C30 mL\u002Fmin documented on the electronic health record at any time within the past three months;\n16. Known hyperkalemia documented on the electronic health record at any time within the past three months;\n17. Liver cirrhosis;\n18. Inflammatory bowel disease;\n19. History of asthma, urticaria or allergic reactions after taking NSAIDs or aspirin;\n20. Allergy to cephalosporins or history of anaphylaxis to penicillin; (u) Inability to provide informed consent.\n\nExclusion criteria (i) through (s) are known contraindications to NSAIDs.",{"count":383,"type":22},884,[227],"Cellulitis is a painful bacterial skin infection commonly seen in Canadian emergency departments. Cellulitis has a negative impact on patients' quality of life and productivity. While this is a bacterial infection, there is evidence inflammation also contributes to the disabling symptoms of pain, redness and swelling. Some studies have suggested that a nonsteroidal anti-inflammatory drug (NSAID) such as naproxen in addition to antibiotics may control inflammation and speed recovery. However, these studies have had too few patients to tell if there is a true benefit.\n\nThe investigators are proposing a randomized controlled trial of patients with cellulitis to compare oral naproxen (500 mg twice daily) plus oral antibiotics versus placebo plus oral antibiotics. The investigators will compare the proportion of patients who have an early clinical response (reduction in area of redness ≥20% at 72 hours), cure, treatment failure, adverse events, and hospital admission.\n\nIf naproxen proves to be superior to placebo, this simple, low-cost intervention will speed time to recovery with less pain for patients, and may potentially reduce treatment failure and time missed from activities. The results of this trial will help inform future cellulitis treatment guidelines.",[387,388,28,389],"Cellulitis","Skin Disease, Infectious","Skin and Soft Tissue Infections (SSTIs)",[391,392,387,393,394,395,396,397],"Infectious Diseases","Emergency Medicine","naproxen","antibiotics","oral antibiotics","cephalexin","anti-inflammatories","2026-07-03",{"date":400,"type":44},"2026-07-07",{"date":74,"type":22},{"date":403,"type":22},"2031-12-01",{"name":405,"class":51},"Ottawa Hospital Research Institute",{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":416,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":138},"100646938","molecular-microbiology--guided-antimicrobial-stewardship-versus-standard-stewardship-in-hospitalized-patients-100646938","NCT07684300","Molecular Microbiology- Guided Antimicrobial Stewardship Versus Standard Stewardship in Hospitalized Patients","Impact of Molecular Microbiology Integrated With Clinical Data on Antimicrobial Therapy Optimization: An Open-Label Cluster-Randomized Crossover Trial","PROACT","Inclusion Criteria:\n\n* Age ≥18 years\n* Hospitalized in one of the participating study units at Hospital General Universitario de Elche.\n* Initiation of empiric high-impact antimicrobial therapy subject to antimicrobial stewardship program (ASP) review.\n* Provision of written informed consent by the participant or, when applicable, by a legally authorized representative.\n\nExclusion Criteria:\n\n* Severe immunosuppression with profound neutropenia (\\\u003C100 neutrophils\u002Fmm³).\n* Previous enrollment in this clinical trial.\n* Expected survival of less than 48 hours.\n* Documented microbiological identification of the presumed causative pathogen by conventional methods in a representative and\u002For sterile sample before randomization and before availability of multiplex molecular microbiology results.",{"count":415,"type":22},250,[89],"The goal of this clinical trial is to learn whether integrating rapid multiplex molecular microbiology results with predefined clinical and laboratory criteria into an antimicrobial stewardship program improves antimicrobial use in hospitalized adults receiving empiric high-impact antimicrobial therapy.\n\nThe main questions it aims to answer are:\n\nDoes this strategy reduce the duration of exposure to high-impact antimicrobial therapy compared with standard antimicrobial stewardship practice? Does this strategy improve the appropriateness of antimicrobial treatment? Does this strategy affect clinical outcomes, including hospital readmission, intensive care unit admission, infection recurrence, mortality, and healthcare costs? Researchers will compare a protocolized antimicrobial stewardship strategy that incorporates multiplex molecular microbiology results and predefined clinical criteria with the standard antimicrobial stewardship strategy currently used in the hospital.\n\nParticipants will:\n\nReceive antimicrobial management according to the stewardship strategy assigned to their hospital unit during the study period.\n\nUndergo molecular microbiology testing and routine clinical and laboratory assessments as part of standard hospital care when indicated.\n\nBe followed to evaluate antimicrobial exposure, treatment appropriateness, safety outcomes, hospital readmission, intensive care unit admission, infection recurrence, mortality, and healthcare costs.",[28,419,305,420],"Antimicrobial Stewardship Program","Multiplex PCR",[420,422,423,305,424,425,426,427,428],"Molecular Microbiology","Antimicrobial Stewardship","Antibiotic Optimization","Antimicrobial Therapy","infectious Diseases","Cluster Randomized Trial","Crossover Trial","2026-07-01",{"date":364,"type":44},{"date":432,"type":44},"2026-04-10",{"date":434,"type":22},"2027-06",{"name":436,"class":51},"Maria Espinosa Perez",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":4},"100616741","the-extended-study-of-prevalence-of-infection-in-intensive-care-iv-100616741","NCT07309549","The Extended Study of Prevalence of Infection in Intensive Care IV","The Extended Study of Prevalence of Infection in Intensive Care IV (EPIC IV)","EPIC IV","Inclusion Criteria:\n\n* All adult patients (\\>18 years) treated in the participating ICUs on the study day.\n\nExclusion Criteria:\n\n* Patients under 18 years",{"count":446,"type":22},10000,"The goal of this observational study is to learn how common infections are in intensive care units (ICUs) around the world and how they are treated. The study will look at all adults in the ICU during a single 24-hour period. The main questions it aims to answer are:\n\n* What types of infections and antibiotic-resistant bacteria are most common in ICUs worldwide?\n* How do resistance patterns affect how participants are treated and how they recover?\n\nHow are antibiotics used in ICUs, and how do hospitals practice antibiotic stewardship?\n\n* What organ support treatments do participants with infections receive?\n* What are the outcomes of participants with severe infections, including survival at hospital discharge (up to 60 days)?\n\nResearchers will compare ICUs across regions and income levels to see how infection patterns, treatments, and outcomes differ around the world.\n\nParticipants will:\n\n* Be counted if they are present in the ICU at any time during the study day.\n* Have information collected from their medical record about their health, the infection they may have, treatments they receive, and their outcome at ICU and hospital discharge (up to 60 days).\n\nBecause this is an observational study, participants will not receive any new treatments as part of the study.",[30,28],[450,451,452,453,454,455],"Intensive Care Unit","Critical Illness","Severe Infection","Organ Dysfunction","ICU Outcomes","Global Prevalence","2026-06-24",{"date":458,"type":44},"2026-06-29",{"date":460,"type":22},"2027-02-01",{"date":434,"type":22},{"name":463,"class":51},"Universidad de la Sabana",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":23,"phases":473,"briefSummary":474,"conditions":475,"keywords":478,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":490,"leadSponsor":492,"locationsCount":494},"100641892","automated-insulin-delivery-versus-daily-injections-for-hospital-diabetes-care-100641892","NCT07645079","Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care","Inpatient Diabetes Management With Automated Insulin Delivery Systems Compared to Multiple Daily Injections With a Basal-bolus Regimen - a Randomized Controlled Trial","Inclusion Criteria:\n\n* A documented history of Type 2 diabetes mellitus (T2DM) which requires subcutaneous insulin therapy\n* acute infectious disease of any kind\n* age ≥ 18 years old\n* willingness and ability to comply with theclinical investigation plan\n* ability to communicate with the trial personal\n* an expected length of hospital stay for at least 2 days after enrolment\n\nExclusion Criteria:\n\n* Patients already using AID for their glycemic management\n* Patients in use of an insulin pump\n* Skin pathologies that hinder application of a FreeStyle Libre-3 CGM and mylife YpsoPump\n* Participation in another trial, which could influence the outcome of the trial\n* Any mental condition rendering the patient incapable of giving informed consent\n* Known or suspected allergy to adhesive material\u002Ftape of the Libre-3-sensor and\u002For YpsoPump\n* Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient\n* Diagnoses\u002Ftreatments\u002Fclinical parameters prohibiting use of Insulin\u002FAID such as\n\n  * Estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m2 OR\n  * Treated with hydroxyurea\u002Fhydroxycarbamide OR\n  * Nutritional therapy (continuous enteral or parenteral feeding) OR\n  * Clinically relevant pancreatic disease OR\n  * Aystemic glucocorticoid treatment with prednisone equivalent dose \\>5 mg\u002Fday OR\n  * Expected to require admission to the intensive-care unit OR \\> Patients in dialysis",{"count":472,"type":22},92,[89],"Aim\n\nThe investigators aim to investigate if automated insulin delivery systems (AID) improve in-hospital glycemic and clinical outcomes in patients with type 2 diabetes compared to standard-of-care with a pen-basal-bolus insulin regimen manually titrated by general staff at Herlev-Gentofte Hospital and a clinical decision support system (GlucoTab) titrating the basal-bolus regimen automatically daily at Graz University Hospital.\n\nPopulation\n\nHospitalized patients with type 2 diabetes in non-intensive care units (non-ICU) at medical wards at Copenhagen University Hospitals of Herley-Gentofte (affiliated with Steno Diabetes Center Copenhagen) and Medical University Hospital of Graz (N = 92).\n\nDesign\n\nThis is an investigator-initiated, two-armed, two-site, prospective, randomized, open-label, blinded endpoint (PROBE) trial.\n\nObjectives\n\nThe objective is to determine the glycemic and clinical effects of inpatient AID systems in non-ICU patients with type 2 diabetes. Participants will be randomized in a usual-of-care and an AID arm. Diabetes management will be performed by usual care in the control arm based on a basal-bolus insulin regimen and point-of-care (POC) glucose testing. A continuous glucose monitoring (CGM) system (Abbott FreeStyle Libre 3) will be used in all groups for outcome analysis and comparison between the groups. The CGM will be blinded for the control arm, to not interfere with the usual of care because of the higher amount of glucose data. The AID-arm will be managed by an AID system with real-time CGM data transmitted to nursing stations.\n\nOutcomes\n\nPrimary outcome: The primary outcome is the difference in CGM-recorded time in range (TIR) (70-180 mg\u002Fdl (3.9-10.0 mmol\u002Fl)) between the POC- and the CGM-arm according to the 2023 in-hospital CGM consensus during the entire hospital stay.\n\nSecondary outcomes: Outcomes are reported according to the 2023 in-hospital CGM consensus and specified in the protocol during the entire hospital stay, including three levels of time above range (TAR) 180-250mg\u002Fdl (10.0-13.9 mmol\u002Fl), \\>250mg\u002Fdl (\\>13.9 mmol\u002Fl), and \\>180mg\u002Fdl (\\>10.0 mmol\u002Fl); three levels of time below range (TBR) 54-70mg\u002Fdl (3.0-3.9 mmol\u002Fl), \\\u003C54mg\u002Fdl (\\\u003C3.0 mmol\u002Fl), and \\\u003C70mg\u002Fdl (\\\u003C3.9 mmol\u002Fl); events of hypoglycemia in three levels, 54-68mg\u002Fdl (3.0-3.8 mmol\u002Fl), \\\u003C54mg\u002Fdl (\\\u003C 3.0 mmol\u002Fl), and \\\u003C70mg\u002Fdl (\\\u003C3.9 mmol\u002Fl), where the glucose values between the two hypoglycemic events must all be \\>70mg\u002Fdl (\\>3.9 mmol\u002Fl) for at least 15 consecutive minutes(1), including prolonged hypoglycemic events (\\> 120 minutes), recurrent hypoglycemic events (events preceded by another hypoglycemic event), and recurrent hypoglycemic days (percentage of days with at least one hypoglycemic event on separate days that is preceded by another in-hospital day with hypoglycemia(1)); mean glucose level; standard deviation (SD) of the CGM glucose distribution; coefficient of variation (CV); and insulin doses during hospitalization.\n\nClinical outcomes: The investigator assess the length of hospital stay as calculated from time of admission until discharge; in-hospital mortality; admissions to intensive care unit; any in-hospital-related complications occurring at least one day after randomization and until discharge, as documented and defined by the treating physician in the electronic health record (e.g., acute kidney injurie, sepsis, etc.)\n\nMethod\n\nFor the usual-of-care-arm, glucose assessment is done by standard POC glucose testing and insulin is manually titrated by general staff at Herlev-Gentofte Hospital and the glucose assessment is done by standard POC glucose testing and insulin is manually titrated by the GlucoTab system titrating the basal-bolus regimen automatically daily at Graz University Hospital. For the AID-arm, CGM data informs in real time the mylife Ypsopump for automated insulin delivery.\n\nDevice\n\nThe investigational device is the AID system, containing of the mylife YpsoPump and the FreeStyle Libre 3 sensor.",[476,28,477],"Diabetes Mellitus Type 2","CGM",[479,480,477,481,482,483,484,485],"automated insulin delivery systems","AID","continouse glucose monitoring","infectiouse disease","type 2 diabetes mellitus","diabetes mellitus type 2","GlucoTab","2026-06-08",{"date":488,"type":44},"2026-06-12",{"date":429,"type":22},{"date":491,"type":22},"2027-07-30",{"name":493,"class":51},"Steno Diabetes Center Copenhagen",2,{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":515,"locationsCount":517},"100638206","multicenter-validation-of-a-risk-prediction-model-for-mdrgnb-infection-100638206","NCT07603128","Multicenter Validation of a Risk Prediction Model for MDRGNB Infection","Prospective Validation of a Risk Prediction Model for MDRGNB Infection: A Multicenter Real-World Prospective Study","PRIOR","Inclusion Criteria:\n\n* Age ≥18 years;\n* ICU stay ≥48 hours;\n* At least one clinical microbiological specimen collected and submitted for testing within 48 hours of ICU admission, with the first submission time designated as the index time;\n* Core predictive variables of the model extractable from electronic medical records or laboratory information systems.\n\nExclusion Criteria:\n\n* For patients with multiple ICU admissions, only the first ICU stay was retained;\n* Missing or indeterminate primary outcome;\n* Missing key predictive variables that could not be handled according to prespecified rules.",{"count":60,"type":22},"This prospective multicenter validation study aimed to evaluate the predictive performance of a previously developed model for MDRGNB infection in ICU patients.",[28],[507,508,509,28],"Prediction model","MDRGNB","ICU","2026-05-22",{"date":512,"type":44},"2026-05-27",{"date":510,"type":44},{"date":48,"type":22},{"name":516,"class":51},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",11,{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":534,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":114},"100579855","ttv-based-management-of-long-term-immunosuppression-in-kidney-transplantation-100579855","NCT06829719","TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","Personalization of Maintenance Immunosuppression Based on TTV Viral Load to Prevent Long-term Complications in Renal Transplantation","TAOIST","Inclusion Criteria:\n\n* Adult ≥ 18 years-old\n* Recipient of a kidney allograft (third graft at most)\n* 12 to 48 months post-transplantation\n* Stable graft function (defined as: delta creatininemia over the previous 6 months \\\u003C 20% and proteinuria \\\u003C 30mg\u002Fmmol)\n* On maintenance immunosuppression, which includes CNI (cyclosporin or tacrolimus) and MMF (Cellcept or Myfortic) with or without corticosteroids\n* Detectable TTV DNAemia at enrollment\n* No circulating DSA in solid phase assay\n* Undetectable BKV DNAemia at enrollment\n* Written informed consent\n\nExclusion Criteria:\n\n* Recipient of an HLA identical graft\n* Mutiple organ transplantation or functional transplant other than kidney\n* Maintenance immunosuppression that includes a mTOR inhibitor, belatacept or imurel\n* Presence of histological sign of active rejection (i+t \\> 2 and g+cpt \\> 2) on graft biopsy performed within 3 months before enrollment\n* Uncontrolled infection at inclusion\n* Infection requiring hospitalization within 3 months before inclusion\n* Diagnosis of a cancer of interest between the (current) transplantation and inclusion\n* Pregnant, unwillingness to practice adequate contraception or patient with a pregnancy plan during 3 years of study\n* Person not affiliated to a social security scheme or beneficiary of a similar scheme\n* Person subject to a legal protection measure (guardianship, curatorship) or deprived of liberty",{"count":527,"type":22},600,[89],"Long-term outcomes in kidney transplantation remain a significant challenge, as complications such as donor-specific antibodies (DSA), antibody-mediated rejection, infections, and cancer increasingly threaten graft and patient survival over time. The development of non-invasive biomarkers to guide the management of therapeutic immunosuppression beyond the first year post-transplantation is therefore a crucial unmet need.\n\nTorque Teno Virus (TTV), a non-pathogenic virus with a high prevalence worldwide, has emerged as a promising biomarker in this context. Its replication inversely reflects immune control by T cells, correlating with the depth of therapeutic immunosuppression. Additionally, its slow replication kinetics make TTV DNAemia a useful marker for evaluating patient adherence to immunosuppressive treatments.\n\nThe TAOIST study tests whether longitudinal monitoring of TTV DNAemia every six months, starting from the second year after transplantation, can guide the personalization of immunosuppressive therapy. The primary endpoint is the time to the first occurrence of complications linked to inadequate immunosuppression, including dnDSA, biopsy-proven rejection, infection, cancer, or graft loss. Secondary objectives include evaluating the acceptability of TTV DNAemia among healthcare professionals and assessing its cost-effectiveness compared to standard care. An ancillary objective examines the link between TTV DNAemia and the immunosuppressant possession ratio (IPR) to explore its potential as a marker of treatment adherence.",[28,531,532,533],"Cancer","Rejection","Kidney Transplantation",[535,536,537,538,239],"TTV","Biomarker","immunosuppression","precision medicine",{"date":512,"type":44},{"date":541,"type":44},"2025-04-23",{"date":543,"type":22},"2031-02-02",{"name":545,"class":51},"Hospices Civils de Lyon",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":554,"maxAge":555,"enrollmentInfo":556,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":558,"conditions":559,"keywords":566,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":138},"100601389","the-peripheral-muscle-oxygenation-and-perfusion-score-as-a-new-non-invasive-tool-to-predict-elevations-in-c-reactive-protein-levels-in-neonates-100601389","NCT07109856","The Peripheral(-Muscle) Oxygenation and Perfusion Score as a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates","The Peripheral(-Muscle) Oxygenation and Perfusion Score (POPScore) a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates - a Prospective Phase II Observational Study","POP-Score","Inclusion Criteria:\n\n* birth weight ≥ 2000 grams\n* Signs of respiratory distress at time-point of inclusion (tachypnoea \\>60\u002Fmin, grunting, intercostal\u002Fsubcostal\u002Fjugular retractions, nasal flaring, supplemental oxygen or respiratory support)\n* Decision to conduct full life support\n* Written informed consent obtained within the first 6 hours after birth, before inclusion in the study\n* Age \\\u003C 6 hours\n\nExclusion Criteria:\n\n* No decision to conduct full life support\n* No written informed consent\n* Birth weight \\\u003C 2000 grams\n* Age \\> 6 hours\n* Severe congenital malformations,\n* Umbilical cord artery pH \\\u003C7.20","0 Hours","6 Hours",{"count":557,"type":22},93,"This is a prospective, single-center Phase II observational study investigating the predictive value of the \"Peripheral(-muscle) Oxygenation and Perfusion Score\" (POP-Score), a novel non-invasive composite index, for early detection of infection\u002Finflammation in neonates. The POP-Score combines peripheral muscle oxygenation measured via near-infrared spectroscopy (NIRS) with routinely monitored clinical parameters (heart rate, oxygen saturation, systolic blood pressure, and subcutaneous fat thickness). The study aims to determine the optimal cut-off value of the POP-Score measured within the first 6 hours after birth to predict elevated C-reactive protein (CRP ≥20 mg\u002FL) within 48 hours. Additionally, multi-site NIRS measurements (cerebral, peripheral muscle, intestinal, and flank) will be evaluated to assess their association with inflammation. The study includes term and moderate-to-late preterm neonates (birth weight ≥2000g) with respiratory distress, admitted to the neonatal intensive care unit at the Medical University of Graz.",[560,561,562,563,564,28,565],"Prematurity, Infections","NIRS","Near Infrared Spectroscopy","Preterm Neonates","Term Infant","Neonatal Sepsis, Early-Onset",[561,567,552,568,569],"near-infrared spectroscopy","neonates","preterm neonates","2026-05-12",{"date":572,"type":44},"2026-05-14",{"date":574,"type":44},"2025-11-27",{"date":576,"type":22},"2028-05-01",{"name":578,"class":51},"Medical University of Graz",{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":145,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":138},"100230861","validation-of-drug-assays-in-various-biological-matrices-100230861","NCT02283112","Validation of Drug Assays in Various Biological Matrices","Inclusion Criteria:\n\n* \\> 18 years of age\n\nExclusion Criteria:\n\n* Unable to give informed consent",{"count":586,"type":22},100,"This study aims to ensure that assays that measure drug concentrations are accurate and precise in different matrices when quantified using high performance liquid chromatography -tandem mass spectrometry (HPLC-MS\u002FMS). The study involves collecting samples of various bodily fluids to quantify antimicrobials, antivirals, oral contraceptives and erectile dysfunction agents. Samples will also be obtained from individuals not receiving these medications for quality control purposes.",[28],"2026-05-06",{"date":591,"type":44},"2026-05-11",{"date":593,"type":44},"2014-10",{"date":595,"type":22},"2027-12-31",{"name":597,"class":51},"University of Liverpool",{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":607,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":138},"100637420","phase-3-continuous-antibiotic-infusion-in-children-100637420","NCT07575009","Continuous Antibiotic Infusion In Children","Inclusion Criteria:\n\n* iv-antibiotic treatment is necessary\n* clinically stable\n* no need to stay in hospital\n* pump or cassette can be changed at the hospital or at home\n* care givers are able to contact hospital if needed\n* clinical diagnose is not uncertain\n* no allergy for the used antibiotic\n* the continuous antibiotic infusion hasn't been started yet or it has been initiated no more than 24 hours prior to study enrolment\n\nExclusion Criteria:\n\n* the pump cannot be carried with the child\n* the child must stay at the hospital for monitoring or other reason\n* unclear diagnose","16 Years",{"count":606,"type":22},150,[227],"Continuous intravenous antibiotic infusion using elastomeric pumps is well established in adult care and has been shown to be effective, safe, and cost-efficient, particularly for beta-lactams and vancomycin. In pediatric outpatient parenteral antimicrobial therapy (p-OPAT), home intravenous treatment is feasible and safe, improves quality of life, and reduces hospital stays and healthcare-associated infections. Elastomeric pumps offer practical advantages, including portability, ease of use, fixed infusion rates, and reduced drug handling, although they are limited by fixed flow rates and drug stability.\n\nThis prospective study at Tampere University Hospital (Tays) will evaluate the safety and cost-effectiveness of 24-hour continuous antibiotic infusions in children between January 2026 and January 2029. Eligible pediatric patients requiring intravenous antimicrobial treatment and suitable for home care will be included. Indications include serious bacterial infections such as bacteremia, osteomyelitis, septic arthritis, neutropenic fever, cystic fibrosis-related infections, and foreign body infections. The study antibiotics are benzylpenicillin, cloxacillin, piperacillin\u002Ftazobactam, and vancomycin, administered via CE-approved infusion devices for home use.\n\nChildren will receive continuous infusion either initially in hospital or directly from the emergency department if appropriate, with treatment duration and dosing comparable to standard intermittent regimens. Outcomes include safety, feasibility, cost-effectiveness, and patient-reported quality of life measured using PedsQL™. The study aims to determine whether continuous infusion can optimize pediatric antimicrobial care and healthcare resource utilization. Results will be published in peer-reviewed international journals.",[28],[611,612,613,614,615],"Continuous antibiotic infusion","Children","sepsis","osteomyelitis","Elastomeric pump","2026-05-04",{"date":618,"type":44},"2026-05-08",{"date":620,"type":44},"2026-04-21",{"date":622,"type":22},"2031-12-31",{"name":624,"class":51},"Tampere University Hospital",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":23,"phases":634,"briefSummary":635,"conditions":636,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":645,"locationsCount":138},"100586868","stop-sepsis-through-home-monitoring-cooperative-100586868","NCT06920979","Stop Sepsis Through Home Monitoring Cooperative","Stethoscoop","Inclusion Criteria:\n\n* This study will include patients aged 18 years or older, capable of giving informed consent, presenting with signs of severe acute infection with a risk of developing sepsis at the emergency department or at their primary care physician.\n\nExclusion Criteria:\n\n* Patients that are severely ill and require immediate hospitalization Qucik Sepsis Related Organ Failure score (QSOFA) ≥ 1 National Early Warning Score (NEWS) ≥ 5\n* Patients that demonstrate confusion, changes in mental state and\u002For an Mini-Mental State Examination (MMSE) below 26\n* Presence of neuropenic fever\n* Patients currently undergoing immunosuppressive therapy or chemotherapy\n* Patients with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)\n* Suspicion of appendicitis, suspicion of meningitis or meningeal irritation, suspicion of or high risk of developing endocarditis\n* Complicated operation wounds at the time of screening\n* Proven pneumonia (CURB 65 score ≥ 1)\n* Emphysema, Chronic Obstructive Pulmonary Disease (COPD) GOLD \\>1 or interstitial lung disease\n* Patients with oxygen at home \\> 2 l\u002Fmin on a chronic basis (severe underlying lung disease?)\n* Severe cardiovascular disease including:\n\n  * Severe heart failure New York Heart Association (NYHA) class \\> 1\n  * Endoprosthesis\n  * Cardiac arrhythmia including atrial fibrillation\n  * Severe heart valve abnormalities\n  * Mechanic valve replacement\n  * Recent acute myocardial infarct or coronarography (less than 1y ago)\n  * Severe peripheral vascular morbidity\n* Acute chest pain (suspicion of acute coronary pathology)\n* Suspicion of\u002Fchance of septic arthritis",{"count":633,"type":22},120,[89],"In this study, patients presenting with acute infections at risk of developing sepsis will be followed in their home setting using wearables that provide (semi-)continue monitoring of vital signs as well as through follow up using a designated smartphone application. This is an innovative pilot study that will examine the potential of transmural care through telemonitoring for the first time in patients at risk for developing sepsis. By allowing for active follow-up of vital parameters in a transmural setting, this project aims to reduce the number of hospitalizations as compared to current practice. Furthermore, we aim to the number of patients referred to the emergency department after a visit at their primary care physician. Thereby, we aim to reduce the healthcare burden, yet providing the ability for rapid intervention in case of detarioration of patients, thereby reducing morbidity and mortality as well as associated costs.",[30,637,28,638],"Home Monitoring Follow-up","Innovativeness","2026-04-27",{"date":641,"type":44},"2026-05-01",{"date":643,"type":44},"2025-02-01",{"date":48,"type":22},{"name":646,"class":51},"University Hospital, Antwerp",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":145,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":656,"conditions":657,"keywords":658,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":494},"100250950","biomarkers-in-infection-100250950","NCT02545478","Biomarkers in Infection","Early Detection of Inflammatory Biomarkers in Infection","Inclusion Criteria for Infected subjects:\n\n* Age 18 years of age or older\n* Confirmed or suspected infection\n\nInclusion Criteria for Control Subjects:\n\n* Age 18 years of age or older\n* A non-infectious clinical presentation to include\n* Normal white blood cell count ( \\> 4,000 and\u002For \\\u003C 12,000)\n* Normothermia ( \\> 96.5 and\u002For less 100.4)\n* Absence of the following clinical complaints: productive cough, fever, pyuria, rash\n* No evidence of acute coronary syndrome\n\nExclusion Criteria for Control Subjects:\n\n\\- Suspected infection",{"count":655,"type":22},4200,"The purpose of this investigation is to evaluate how early biomarkers of infection and inflammation perform in identifying patients at risk for poor outcome in sepsis and septic shock.",[30,28,127],[659,32,660,661,662],"septic shock","inflammation","pathologic process","biomarkers","2026-04-13",{"date":665,"type":44},"2026-04-15",{"date":667,"type":4},"2006-04",{"date":669,"type":22},"2031-12",{"name":671,"class":51},"Beth Israel Deaconess Medical Center",{"id":673,"slug":674,"hasResults":12,"nctId":675,"briefTitle":676,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":12,"sex":18,"minAge":679,"maxAge":4,"enrollmentInfo":680,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":682,"conditions":683,"keywords":692,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":138},"100634157","potential-of-interface-care-models-to-deliver-more-appropriate-care-to-patients-with-acute-medical-illness-100634157","NCT07536035","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness in Singapore and Decrease Utilisation of Acute Care Bed-days","Inclusion Criteria:\n\n* AMU inclusion criteria - admission from ED to AMU directly\n* Control group inclusion criteria - admission from ED to GW directly\n* Acute medical illnesses that includes infection-related conditions, falls-disequilibrium, and acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).\n\nExclusion Criteria:\n\n* Below 21 years old\n* Patients undergoing active chemotherapy\n* Patients with active pregnancy\n* Patients admitted less than 24 hours\n* Cerebrovascular disease requiring thrombolysis or intravascular intervention","21 Years",{"count":681,"type":22},220,"Every country in the world is experiencing growth in both the size and the proportion of older persons. As a result of the changes, the profile and needs of people with medical illnesses have evolved. How care is delivered to patients has to keep pace with these changes, or patients will experience poor care at high cost and not have their needs met. A new model of care has emerged to meet these challenges: Acute Medical Unit. Despite considerable investment and popularity of this model, questions remain: (i) Who benefits most from this care model? (ii) How may these models be most effectively implemented for the best results? (iii) How effective are these models? Singapore is well-placed to answer these questions with its national healthcare system and excellent research institutions. The investigators plan to study how effective the model is by comparing patients with similar profiles exposed to both these care models compared to how hospital care is usually provided, looking for four differences: (i) how long patients stay in hospital, (ii) how often they use the emergency department (iii) quality of health (iv) cost. Additionally, the investigators seek to characterise patterns of health needs for this group of patients.",[684,685,686,687,28,688,689,690,691],"Falls Injury","Falls","Hospitalization in Acute Care","Chronic Obstructive Pulmonary Disease (COPD)","Acute Exacerbation of Asthma","Pneumonia","UTI - Urinary Tract Infection","URTI - Viral Upper Respiratory Tract Infection",[693,694,695,696,697,698,699],"Acute Medical Unit","Acute Medicine","Interface Care","Clinical effectiveness","Cost effectiveness","prospective observational","matched controlled",{"date":701,"type":44},"2026-04-17",{"date":703,"type":44},"2024-09-30",{"date":705,"type":22},"2026-05-31",{"name":707,"class":51},"National University Hospital, Singapore",{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":713,"acronym":714,"eligibilityCriteria":715,"healthyVolunteers":12,"sex":18,"minAge":554,"maxAge":716,"enrollmentInfo":717,"targetDuration":4,"studyType":23,"phases":719,"briefSummary":720,"conditions":721,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":725,"lastUpdatePostDateStruct":726,"startDateStruct":727,"completionDateStruct":729,"leadSponsor":731,"locationsCount":494},"100630204","phase-4-a-study-to-compare-the-efficacy-and-safety-of-extended-and-intermittent-infusion-of-beta-lactams-in-critically-ill-paediatric-patients-100630204","NCT07484633","A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","A Protocol of a Randomised, Two-arm Superiority Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","PEBBLE","Inclusion Criteria:\n\n* paediatric patients (0-17 years of age) with suspected or confirmed bacterial infection who are treated in a PICU or NICU and diagnosed with sepsis with a total Phoenix Sepsis Score ≥2 points, and the infection is clinically probable or confirmed by microbiological culture (e.g. from a blood culture, cerebrospinal fluid, urine, trachea, wound, etc.), excluding contamination;\n* who are receiving β-lactams including meropenem, piperacillin\u002Ftazobactam, cefepime and ceftriaxone;\n* who received the same β-lactam therapy within 24 hours prior to inclusion or started new β-lactam therapy due to clinical deterioration;\n* written consent of the parent or guardian is obtained.\n\nExclusion Criteria:\n\n* palliative care patients;\n* patients participating in other drug trials;\n* patients with impaired renal function if dosing modification is required (estimated Glomerular Filtration Rate \\[eGFR\\]\\\u003C50 mL\u002Fmin\u002F1.73m2 for meropenem, cefepime, and piperacillin\u002Ftazobactam; eGFR\\\u003C10 mL\u002Fmin\u002F1.73m2 for ceftriaxone);\n* patients undergoing plasmapheresis (TPE);\n* patients undergoing extracorporeal therapy (continuous kidney replacement therapy \\[CKRT\\] or extracorporeal membrane oxygenation \\[ECMO\\]);\n* β-lactam allergy;\n* patients admitted from another institution or department who have been on the same β-lactam treatment for more than 24 hours;\n* pregnancy.","17 Years",{"count":718,"type":22},110,[25],"The goal of this clinical trial is to examine the success and safety of administering certain antibiotics (beta-lactams) given in a longer 3-hour infusion to children (0-17 years) who are critically ill and have severe infection.\n\nThe main question it aims to answer is:\n\nIs the longer infusion more effective than the conventional short-term (0.5-hour-long) infusion? Researchers will compare the 3-hour-long infusion group to the 0.5-hour-long infusion group to determine whether the longer infusion can cure the infection earlier and whether it is equally safe. The doses are the same in the two groups. Only the duration differs until the patient receives the antibiotic.\n\nParticipants will:\n\n* be given the required antibiotic drug in a 3-hour-long or in a 0.5 hour-long infusion.\n* be examined to make sure their blood drug levels are correct. This will require two blood tests.\n* be treated according to routine care and have examinations and blood tests performed.",[28,30,722,723,724],"NICU","PICU","Beta Lactams","2026-04-07",{"date":663,"type":44},{"date":728,"type":22},"2026-04",{"date":730,"type":22},"2028-04",{"name":732,"class":51},"Semmelweis University"]